India Geographical Atrophy Market Research Report: Trends, Forecast & Opportunities (2026-2032)

By Diagnosis Method (Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)), By Age Group (Below 60 Years, Above 60 Years, Above 70 Ye... ... 0 Years, Above 70 Years), By Therapeutic Agents (Late stage (Phase III), Phase II, Phase I, Pre-clinical & Discovery Candidates), By Therapy Type (Complement Inhibitors, Gene Therapy & Regenerative Approaches, Small Molecules & Others), By Drug Class (Anti VEGF Agents, Complement Pathway Inhibitors, Cell and Gene Therapies, Other Therapeutics), By Route of Administration (Intravitreal, Oral, Others), By End User (Hospitals, Ophthalmic Clinics / Specialty Eye Care Centers, Homecare & Others), and others Read more

  • Healthcare
  • Mar 2026
  • 170
  • PDF, Excel, PPT

India Geographical Atrophy Market Report Key Takeaways:

  • The India Geographical Atrophy market size was valued at USD 0.87 billion in 2025 and is projected to grow from USD 0.96 billion in 2026 to USD 1.79 billion by 2032, exhibiting a CAGR of 10.94% during the forecast period.
  • By diagnosis method, the optical coherence tomography angiography (OCT-A) segment represented a significant share of about 39% in the India Geographical Atrophy Market in 2026.
  • By end user, the Hospitals segment represented a significant share of about 58% in the India Geographical Atrophy Market in 2026.
  • Leading companies in the Market are Apellis Pharmaceuticals, Astellas Pharma, Roche Holding AG (Genentech, Inc.), F. Hoffmann‑La Roche, Novartis AG, Regeneron Pharmaceuticals, AbbVie, Alcon, Bausch + Lomb, Santen Pharmaceutical, and Others.

Market Insights & Analysis: India Geographical Atrophy Market (2026-32):

India Geographical Atrophy Market size was valued at approximately USD 0.87 billion in 2025 and is projected to grow from USD 0.96 billion in 2026 to USD 1.79 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 10.94% during the forecast period, i.e., 2026-32.

The India market for Geographic Atrophy is gradually expanding as the burden of retinal degenerative diseases increases alongside demographic aging. Geographic atrophy develops as a late stage of Age-related Macular Degeneration, a condition that causes progressive damage to retinal pigment epithelial cells and leads to irreversible vision impairment. As India’s elderly population grows, the number of patients susceptible to advanced retinal disorders is also increasing, creating sustained demand for early detection, clinical monitoring, and therapeutic management.

Population-based epidemiological studies highlight the rising prevalence of AMD across India. The INDEYE study, which assessed retinal health among elderly individuals aged 60 years and above in North and South India, found that late AMD prevalence reached approximately 1.2% in northern regions, while early AMD indicators such as drusen deposits and pigmentary irregularities were observed in nearly 38% of participants. The study included about 1,995 participants from North India, providing strong evidence that retinal degeneration already affects a significant share of the aging population. These findings suggest that a substantial portion of patients may eventually progress to advanced stages such as geographic atrophy, increasing long-term demand for ophthalmic diagnostic and treatment services.

Technological innovation is also shaping the future of the retinal disease management ecosystem. The growing adoption of artificial intelligence in ophthalmology diagnostics is emerging as a transformative trend that can significantly expand screening capacity. A multicenter research study evaluating an AI-based Diabetic Retinopathy Screening System (AIDRSS) analyzed 5,029 participants and more than 10,058 retinal images across clinical centers in India. The deep-learning system demonstrated 92% sensitivity and 88% specificity in detecting retinal diseases, confirming the effectiveness of AI-driven image analysis as a scalable diagnostic tool . Such systems enable automated identification of retinal abnormalities and allow healthcare providers to screen larger patient populations efficiently, particularly in regions where ophthalmology specialists are limited.

Government initiatives are further strengthening the future growth outlook of the market. In February 2025, the Government of Kerala launched Nayanamritham 2.0, a government-led AI-assisted screening program for chronic eye diseases developed in collaboration with Remidio. The program deploys AI-enabled fundus cameras in primary health centers to screen patients for retinal conditions, including AMD, glaucoma, and diabetic retinopathy. The system automatically analyzes retinal images and identifies suspected cases for referral to ophthalmologists, enabling faster detection and improving access to specialized care across the state.

Overall, rising AMD prevalence, expanding AI-driven retinal diagnostics, and increasing government investment in early eye-disease screening are collectively shaping the future of India’s geographic atrophy market. As screening programs scale and early detection improves, the number of diagnosed patients will increase, creating stronger demand for advanced retinal diagnostics and therapeutic interventions in the coming years.

India Geographical Atrophy Market Recent Developments:

  • 2025: Eyestem Research Pvt. Ltd. announced the successful completion of its Phase-1 clinical trial for Eyecyte-RPE, a stem-cell-derived retinal pigment epithelium therapy designed to treat geographic atrophy. The study demonstrated favorable safety outcomes and early signs of visual improvement in treated patients, supporting the company’s plan to advance the therapy into Phase-2 clinical trials in India .
  • 2025: Apellis Pharmaceuticals released five-year extension study results for SYFOVRE (pegcetacoplan), showing the treatment can delay geographic atrophy lesion progression by approximately 1.5 years. The data strengthen the global clinical evidence base and support potential expansion into emerging ophthalmology markets such as India .

India Geographical Atrophy Market Scope:

 Category  Segments
By Diagnosis Method (Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)),
By Age Group (Below 60 Years, Above 60 Years, Above 70 Years),
By Therapeutic Agents (Late stage (Phase III), Phase II, Phase I, Pre-clinical & Discovery Candidates),
By Therapy Type (Complement Inhibitors, Gene Therapy & Regenerative Approaches, Small Molecules & Others),
By Drug Class (Anti VEGF Agents, Complement Pathway Inhibitors, Cell and Gene Therapies, Other Therapeutics),
By Route of Administration (Intravitreal, Oral, Others),
By End User (Hospitals, Ophthalmic Clinics / Specialty Eye Care Centers, Homecare & Others),

India Geographical Atrophy Market Driver:

Increasing Prevalence of Age-Related Macular Degeneration

The growing prevalence of Age-related Macular Degeneration (AMD) in India is a major factor driving the geographic atrophy (GA) market, as GA represents an advanced stage of AMD characterized by progressive degeneration of retinal pigment epithelium and gradual central vision loss. With India’s aging population expanding, the number of individuals susceptible to retinal degenerative disorders is increasing, creating higher demand for early diagnosis, monitoring technologies, and specialized treatments.

Population-based ophthalmic studies in India highlight the rising burden of AMD. The Central India Eye and Medical Study evaluated 4,711 individuals aged 30 years and above to determine the prevalence of retinal diseases. The findings showed that early AMD prevalence increased to about 8.3% among individuals aged 60 years and older, while late AMD prevalence reached approximately 0.6% in the same age group, indicating that a portion of the elderly population is already progressing toward advanced disease stages such as geographic atrophy .

Further evidence comes from the INDEYE Study, which examined retinal health among elderly populations across North and South India. Among adults aged 60–79 years, the study reported early AMD prevalence of 39.3% and late AMD prevalence of around 1.2%, demonstrating a significant burden of retinal degeneration . In southern regions such as Tamil Nadu and Puducherry, analysis of 2,271 participants showed early AMD signs in about 40.8% of elderly individuals, with late AMD prevalence reaching approximately 1.3%, slightly higher than in northern regions.

Overall, these epidemiological findings indicate that AMD is increasingly affecting India’s elderly population. As demographic aging continues and retinal screening programs expand, the number of patients progressing to geographic atrophy is expected to rise, strengthening long-term demand for advanced diagnostics and therapeutic solutions in the market.

  1. Market Segmentation
  2. Introduction
    1. Product Definition
    2. Research Process
    3. Assumptions
  3. Executive Summary
  4. India Geographical Atrophy Market Policies, Regulations, and Product Standards
  5. India Geographical Atrophy Market Trends & Developments
  6. India Geographical Atrophy Market Dynamics
    1. Growth Factors
    2. Challenges
  7. India Geographical Atrophy Market Hotspot & Opportunities
  8. India Geographical Atrophy Market Outlook, 2022-2032F
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Diagnosis Method- Market Size & Forecast 2022-2032, USD Million
        1. Fundus Autofluorescence (FAF)
        2. Optical Coherence Tomography Angiography (OCT-A)
        3. Multifocal Electroretinography (mfERG)
      2. By Age Group- Market Size & Forecast 2022-2032, USD Million
        1. Below 60 Years
        2. Above 60 Years
        3. Above 70 Years
      3. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
        1. Late stage (Phase III)
        2. Phase II
        3. Phase I
        4. Pre-clinical & Discovery Candidates
      4. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
        1. Complement Inhibitors
        2. Gene Therapy & Regenerative Approaches
        3. Small Molecules & Others
      5. By Drug Class- Market Size & Forecast 2022-2032, USD Million
        1. Anti VEGF Agents
        2. Complement Pathway Inhibitors
        3. Cell and Gene Therapies
        4. Other Therapeutics
      6. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
        1. Intravitreal
        2. Oral
        3. Others
      7. By End User- Market Size & Forecast 2022-2032, USD Million
        1. Hospitals
        2. Ophthalmic Clinics / Specialty Eye Care Centers
        3. Homecare & Others
      8. By Region- Market Size & Forecast 2022-2032, USD Million
        1. North
        2. East
        3. West
        4. South
      9. By Company
        1. Competition Characteristics
        2. Market Share & Analysis
  9. India Fundus Autofluorescence (FAF) Market Outlook, 2022-2032
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Age Group- Market Size & Forecast 2022-2032, USD Million
      2. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
      3. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
      4. By Drug Class- Market Size & Forecast 2022-2032, USD Million
      5. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
      6. By End User- Market Size & Forecast 2022-2032, USD Million
      7. By Region- Market Size & Forecast 2022-2032, USD Million
  10. India Optical Coherence Tomography Angiography (OCT-A) Market Outlook, 2022-2032
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Age Group- Market Size & Forecast 2022-2032, USD Million
      2. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
      3. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
      4. By Drug Class- Market Size & Forecast 2022-2032, USD Million
      5. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
      6. By End User- Market Size & Forecast 2022-2032, USD Million
      7. By Region- Market Size & Forecast 2022-2032, USD Million
  11. India Multifocal Electroretinography (mfERG) Market Outlook, 2022-2032
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Age Group- Market Size & Forecast 2022-2032, USD Million
      2. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
      3. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
      4. By Drug Class- Market Size & Forecast 2022-2032, USD Million
      5. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
      6. By End User- Market Size & Forecast 2022-2032, USD Million
      7. By Region- Market Size & Forecast 2022-2032, USD Million
  12. India Geographical Atrophy Market Key Strategic Imperatives for Success & Growth
  13. Competitive Outlook
    1. Company Profiles
      1. Apellis Pharmaceuticals
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      2. Astellas Pharma
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      3. Roche Holding AG (Genentech, Inc.)
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      4. F. Hoffmann La Roche
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      5. Novartis AG
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      6. Regeneron Pharmaceuticals
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      7. AbbVie
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      8. Alcon
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      9. Bausch + Lomb
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      10. Santen Pharmaceutical
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
  14. Disclaimer


MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

Data Trangulation

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

We’d love to understand what matters most to you.

Your data is 100% confidential & secure

By submitting, you agree to our Terms and Privacy Policy .